The global nutraceutical industry is undergoing a significant transformation, with U.S. and European brands increasingly looking beyond traditional sourcing hubs such as China. Geopolitical shifts, pandemic-related vulnerabilities, and a heightened demand for quality, traceability, and sustainability have propelled India into the spotlight as a strategic and reliable destination for natural...
India’s Role in Medical Devices to Blossom with AI Integration
Artificial Intelligence (AI) is being incorporated into various medical devices, including imaging machines for faster scans and lesion detection, wearables for heart arrhythmia detection, and software systems for predicting sepsis risk in hospitals. This trend has prompted regulators to clarify their positions on AI in medical devices. As this happens,...
U.S., India, Collaborate to Develop Rare Diseases Drugs
On Oct 29 and 30, 2023, the Indo U.S. Bridging RARE Summit was held at George Mason University in Arlington, VA. This Summit brought together key leaders representing all stakeholders of rare diseases from across the world with a specific focus on the U.S., and the Indian subcontinent. At this...
Sun Pharma Plans to Sell Drug for Neonatal Seizures in USA
Mumbai-based Sun Pharma, signed a licensing agreement with Sun Pharma Advanced Research Company (SPARC) to commercialize the drug benzyl alcohol and propylene glycol-free phenobarbital sodium powder, SEZABY for the treatment of neonatal seizures, in the U.S. market. SPARC submitted a new drug application to the U.S. Food and Drug Administration...
2 Drugs from India’s Zydus win USFDA Approval
Zydus Lifesciences has received tentative approval from the FDA to market its Amantadine Extended-Release Capsules in the United States. Amantadine is indicated for the treatment of dyskinesia (sudden uncontrolled movements) in patients with Parkinsons disease who are treated with levodopa therapy, with or without dopaminergic medicines. The pharmaceutical company said that...
India’s Biotech Startup Eyestem Raises $6.4 Mn
Headquartered in Bangalore and Delaware, cell therapy startup Eyestem secured $6.4 million in its Series A funding round at a post-money valuation of $46.4 million. The funding was led by three Indian pharma majors- Biological E. Limited, Alkem, NATCO and Anurag and Karan Bagaria, promoters of Kemwell Biopharma. Existing investors...